The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
DOMA Perpetual Capital Management has launched a formal proxy solicitation to replace three board members at Pacira BioSciences. DOMA, which owns approximately 7.5% of the company's outstanding common stock, is urging shareholders to vote for its three independent candidates. The firm accuses Pacira's management of gross negligence and misleading investors regarding risks to its drug EXPAREL, while advocating for a strategic sale of the company.
This move comes as biotech firms face increasing pressure from activist investors to improve governance, a trend seen across the healthcare sector recently. Per market data, activist pressure often leads to short-term price volatility in targeted stocks. DOMA argues that the current board is gambling with the company's future through risky litigation strategies, necessitating a leadership overhaul to protect shareholder interests.
Sign in to access this content
Sign InAccording to market data, PCRX shares have shown varied performance recently, and traders will watch for price reactions following this announcement. Looking at the economic calendar, investors are awaiting speeches from Fed officials, including Kashkari on May 7, 2026, for broader market sentiment. The primary catalyst to watch will be any formal response from Pacira's board regarding DOMA's demands.